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Abstract
The objective of the research was to investigate the features and association of antihyperglycemic therapy and
cancer in patients with type 2 diabetes mellitus.
Materials and Methods. The study included the analysis of medical records of patients with type 2 diabetes
mellitus who were diagnosed with cancer during 2012-2016. The obtained results were processed by statistical
methods using the software packages Microsoft Excel and Statistika-12. The significance of differences between
the frequency of using different treatment schemes was assessed by the Pearson’s test (χ2). To determine the
risk of predicted events, the odds ratio, the 95% confidence interval, the positive and negative prognostic values
were calculated.
Results. There were diagnosed 533 cases of cancer in patients with type 2 diabetes mellitus. The most
common scheme of antihyperglycemic therapy prior to the detection of malignant diseases was a combination of
metformin and sulfonylurea derivatives (35.65%), as well as monotherapy with sulfonylurea derivatives (17.26%)
and metformin (11.28%). Prior to diagnosing cancer in 396 (74.30%) patients, antihyperglycemic therapy that
included sulfonylurea derivates or insulin was used. Among obese patients 68.82% used sulfonylureas and
insulin as part of antidiabetic therapy before diagnosis of cancer. The connection between insulin therapy and
the risk of cancer development in patients with type 2 diabetes mellitus was proved (the odds ratio=2.35; the
95% confidence interval (1.91 - 2.91); p < 0.001).
Conclusions. Prior to the detection of cancer in patients with type 2 diabetes mellitus, the combination therapy
with metformin and sulfonylurea derivatives was most often used. The association between insulin therapy and
the development of cancer in patients with type 2 diabetes mellitus was revealed. Cancer screening is advisable
for patients with type 2 diabetes mellitus and obesity, who receive as a therapy sulfonylurea derivates and/or
insulin.
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Problem statement and analysis of
the latest research
The increased risk of cancer in patients with dia-
betes mellitus (DM) encourages scientists to study
the mechanisms of association between the two
pathologies. Hyperinsulinemia and hyperglycemia
are recognized as the main pathogenetic factors of
cancer in patients with DM [1]. Chronic exposure
to these factors disrupts the activity of regulatory
systems of cellular activity, metabolism and sur-
vival.
In type 2 DM (T2DM) and obesity, hyperinsu-
linemia and constant nutritional excess cause hyper-
activity of anabolism, protein synthesis, which can
cause disorders of the cell cycle at different stages,
contributing to the influence of oncogenes on the
proliferation and apoptosis processes.
Hyperglycemia contributes to oncogenesis
through indirect and direct procarcinogenic effects.
The indirect effect is caused by the stimulation of
certain organs to the synthesis of growth factors
(insulin / insulin-like growth factor – IGF-1) and
pro-inflammatory cytokines. The direct effect is the
induction of mutations in the cell due to oxidative
stress (OS) and activation of signaling pathways
associated with carcinogenesis.
Under physiological conditions, the processes
of metabolism, proliferation, and apoptosis are con-
trolled by the coordinated interaction of many sig-
naling systems, the activity of which depends on
the influence of factors of their activation and inhi-
bition. One of the most important signaling path-
ways involved in the regulation of oncogenesis and
metabolism in diabetes is the PI3K/Akt/mTORC1
pathway, the main components of which are
phosphoinositide-3-kinase (PI3K), Akt kinase (Pro-
tein kinase B alpha) and mTOR (mechanistic tar-
get of rapamycin kinase) [2]. Activating factors of
PI3K/Akt/mTORC1 are insulin and IGF-1, the level
of which in DM is often increased due to insulin
resistance and hyperinsulinemia (endogenous and
exogenous) [3].
MTORC1 is a key kinase of this pathway, which
regulates the processes of cell proliferation, apopto-
sis, and metabolism through its effect on the riboso-
mal protein kinase p70S6K and protein synthesis.
The physiological inhibitor of mTORC1 activity
is an activated adenosine monophosphate protein
kinase (AMPK), which, if necessary, causes the
reorganization of cellular metabolism to the mode
necessary to restore energy balance in the cell [4].
However, under conditions of prolonged nutrient
and energy overload in T2DM, AMPK function
may be insufficient.
The chronic clinical course of DM and the need
for continuous daily treatment led to a sound scien-
tific study of possible mechanisms of association of
the two diseases through the influence of antihyper-
glycemic therapy (AHGT).
Due to the progressive development of scien-
tific and practical medicine, nowadays, diabetics
have access to a wide range of antihyperglycemic
drugs (AHGD) with different mechanisms of ac-
tion, which are taken into account when choosing
a treatment for patients at different stages of DM,
considering insulin-producing capacity of the pan-
creas, side effects and accompanying diseases in
each individual case.
Patients with type 1 DM are known to require in-
sulin replacement therapy, and patients with T2DM
traditionally start their therapy with AHGD in tablet
form, however, with time, many of them require
treatment with insulin either.
To date, different types of insulin and tablet
AHGD of high-quality are available for patients.
According to the mechanism of action, tablet antidi-
abetic drugs are divided into:
1. Insulin sensitizers (biguanides and thiazolidine-
diones);
2. Secretagogues: sulfonylurea derivatives (SUD)
and benzoic acid derivatives;
3. Stimulators of incretin hormones activity (in-
cretinomimetics): glucagon-like peptide-1 ana-
logues (aGLP-1) and dipeptidylpeptidase-4
inhibitors (iDPP-4);
4. Drugs that inhibit the absorption of glucose
into the blood through the intestine
(α-glucosidase inhibitors);
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5. Drugs that block the reabsorption of glucose
by the kidneys (sodium-glucose co-transporter-
2 (SGLT2) inhibitors).
Given the ability of AHGD to lower blood glu-
cose levels, it is natural and obvious that all groups
of antidiabetic drugs inhibit the processes of car-
cinogenesis caused by hyperglycemia. On the other
hand, different mechanisms of action of drugs cause
additional pleiotropic effects due to their modify-
ing effect on other diabetes-dependent cancer risk
factors.
Metformin, which is the drug of choice in the
treatment of patients with T2DM, has the best on-
coprotective properties. Recent studies have shown
that metformin therapy reduces the risk of cancer of
the lungs [5], colorectal localization [6], ovaries [7],
mammary glands [8], and endometrium [9].
SUD currently dominate among second-line
drugs for the treatment of patients with T2DM ow-
ing to their affordability and potent hypoglycemic
effect, including people with oncological
diseases [10]. Studies proved the prooncogenic
effect of drugs in this group due to the effects of
hyperinsulinemia [11, 12]. The role of iatrogenic
hyperinsulinemia (as a result of insulin therapy) as a
factor of oncogenesis has been proven in many stud-
ies [13], but the results of some studies differ [14].
The objective of the research was to inves-
tigate the features and association of antihyper-
glycemic therapy and cancer in patients with T2DM.
1. Materials and Methods
The study was conducted in accordance with the
guidelines of the Declaration of Helsinki 1975 and
its revised 1983 version. The research was carried
out on the basis of the analysis of medical records of
inpatients and outpatients with T2D who were diag-
nosed with cancer during 2012-2016. The bases for
the study were: the Precarpathian Oncology Cen-
ter, the Ivano-Frankivsk Regional Clinical Hospital,
medical institutions of Ivano-Frankivsk region. The
obtained results were processed by statistical meth-
ods in the software packages Microsoft Excel and
Statistika-12.
The significance of the difference between the
frequency of using different treatment regimens was
assessed by the Pearson’s test (χ2). To determine
the risk of predicted events, the odds ratio (Odd-
sratio, OR), the 95% confidence interval (CI), the
positive and negative prognostic values were calcu-
lated.
Ethics Policy
The study is a fragment of the research project
”Epidemiology of Oncological Diseases in Patients
with Diabetes Mellitus and the Effect of Antihyper-
glycemic Drugs on Oncogenesis Markers” (registra-
tion number 0117U005263), included into the com-
plex research work of the Ivano-Frankivsk National
Medical University ”Pathogenetic Mechanisms of
Development of Changes in Organs of the Respira-
tory, Endocrine, Nervous Systems in the Modeled
Pathological Conditions and Their Correction” (reg-
istration number 0117U001758), without special
funding.
The study protocol was reviewed and approved
by the Ethics Committee of the Ivano-Frankivsk
National Medical University (protocol No 97/17 of
October 19, 2017).
2. Results and Discussion
According to the processed archival data, during
2012-2016, 533 cases of cancer were diagnosed in
patients with T2DM. The most common localiza-
tions of malignant neoplasms (MN) are presented
in Fig. 1.
MN of other localizations were diagnosed in 46
patients with a low frequency, in particular lym-
phatic system cancer was detected with the fre-
quency of every localization case less than 1.5%:
the incidence of thyroid cancer was 1.13%, the brain
– 0.94%, biliary tract, female external genitalia (EG),
nasal sinuses – 0.75%, soft tissues and parotid sali-
vary glands – 0.56%, esophagus and oropharynx –
0.38%, bones, adrenal glands, urinary tract, small
intestine, male EG – 0.19%.
In accordance with the objective of the study,
the analysis of AHGT in patients with T2DM prior
to the detection of cancer was carried out (Table 1).
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Figure 1. MN of the most widespread localizations in patients with T2DM (n=487).
Note: % – percentage of the total number of MN cases.
Table 1. AHGT of patients with T2DM prior to the detection of cancer.
Therapy
Number of patients
(n=533)
Frequency (%)
Diet 60 11.26
Metformin (monotherapy) 63 11.82
Metformin + iDPP-4 9 1.69
Metformin + glitazones 1 0.19
Metformin + SGLT2 inhibitors 2 0.38
Metformin + SUD 190 35.65
Metformin + insulin 49 9.19
Glitazones (monotherapy) 2 0.38
SUD (monotherapy) 92 17.26
Insulin (monotherapy) 56 10.51
Metformin + iDPP-4 + insulin 1 0.19
Metformin + iDPP-4 + SUD 2 0.38
SUD + insulin 6 1.13
According to the results shown in Table 1, the
most common treatment scheme for patients with
T2DM prior to the detection of cancer was a com-
bination of metformin and SUD. This scheme is
traditionally used in the treatment of patients with
T2DM.
A comparative analysis of the number of pa-
tients who used insulin preparations and SUD as
part of AHGT before the detection of cancer was
carried out (Fig. 2).
These groups of AHGD in daily therapy were
found to be taken by 396 patients with T2DM;
137 patients used other groups of antidiabetic agents,
without insulin or SUD.
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Figure 2. Frequency of using SU and insulin drugs as part of AHGT by patients with T2DM prior to the
detection of cancer.
Note: % – percentage of the total number of patients with MN (n=533).
Frequent use of these drugs, obviously, has its
own explanation in each individual case. Tradi-
tionally and naturally, secretagogues and insulin
replacement therapy are prescribed to patients with
insulin deficiency, or in case of contraindications to
AHGD of other groups.
According to the processed data, 279 (52.35%)
patients suffered from obesity with a body mass
index (BMI) > 30 kg/m2, 254 (47.65%) patients
were not obese.
The analysis of the frequency of using these
groups of drugs in obese patients was carried out
(Table 2).
Statistical analysis showed a significantly higher
frequency of using AHGT that included insulin
and/or secretagogues in non-obese patients with
T2DM (P ¡ 0.05). However, it was found that among
279 obese patients,192 patients (68.82%) received
these schemes of treatment (Table 2).
The data obtained confirmed the frequent use
of insulin drugs and SUD in the schemes of AHGT,
including obese patients, which might contribute
to hyperinsulinemia. Based on the archival data
studied, we cannot reliably confirm the presence
of hyperinsulinemia (since insulin levels were not
determined); however, taking into account the value
of BMI (as a sign of insulin resistance), this assump-
tion may be correct.
According to official data presented in the state
statistical reporting form No 12 ”Report on Dis-
eases Registered in Patients Living in the Area
of Treatment and Prevention Facilities” in Ivano-
Frankivsk region during 2012-2016, 42,532 patients
with T2DM were registered; among them, 4,376
people were on insulin therapy, 38,156 patients did
not use insulin.
The analysis of the impact of insulin therapy on
the risk of cancer was performed (Table 3).
Patients with T2DM who use insulin as part of
AHGT were found to have twice the risk of cancer
as compared to patients on other treatment regimens.
In this case, it is impossible to state categorically
about the direct impact of insulin therapy on the
development of cancer, as this statement requires
the additional data, in particular on the duration
of insulin therapy before diagnosing cancer, which
is often not mentioned in patient documentation
used for epidemiological research. A comparative
analysis of cancer risk in patients with other AHGT
schemes would also be appropriate. However, the
lack of a register of patients with T2DM who use
tablet AHGD does not allow determining the risk
of cancer associated with the use of other groups of
antidiabetic drugs.
To date, metformin has the most obvious anti-
tumor activity due to its ability to reduce insulin
resistance and hyperinsulinemia. At the molecu-
lar level, metformin, by activating AMPK, affects
the activity of the PI3K/Akt/mTOR signaling path-
way [1, 15].
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Table 2. Use of SU derivatives and insulin in patients with diabetes and cancer
Total number of Total number of
χ2 pobese patients (n=279) patients without obesity (n=254)
Treated with insulin
and SUD as part of
AHGT
Without insulin and
SUD as part of
AHGT
Treated with insulin
and SUD as part of
AHGT
Without insulin and
SUD as part of
AHGT
192 87 205 49 9.28 0.002
Table 3. The risk of cancer in patients with T2DM is associated with insulin therapy.
Total number
of cancer
patients
Number of patients with
T2DM treated with in-
sulin therapy
Number of patients with
T2DM treated without in-
sulin therapy
OR 95% CI p
Total With MN Total With MN
533 4376 112 38156 421 2.35 1.91 - 2.91 p<0.001
In contrast to metformin, the property of SUD
to stimulate insulin synthesis by β -cells of the pan-
creas explains the possible prooncogenic effect of
these drugs through the effects of hyperinsulinemia
and the activation of signaling pathways involved
in carcinogenesis. The studies have proven this
effect [12, 16].
However, according to a comparative meta-
analysis of many studies, the risk of cancer in pa-
tients taking SUD is ambiguous and depends on
the generation of drugs, their affinity with receptors
of the pancreas and differentiated insulin exposi-
tion [14].
Recent studies have proven the potential onco-
protective properties of SUD, which are associated
with inhibition of vascular endothelial growth fac-
tor (VEGF), which inhibits the neovascularization
of MN and the invasiveness of cancer cells. Chlor-
propamide has been shown to have a selective abil-
ity to inhibit Akt pathway activity in cancer cells,
leading to cell growth arrest and apoptosis of cancer
cells in vitro and in vivo. In addition, SUD reduce
the level of TNF- α and the number of TNF- α re-
ceptors in cancer cells, having a beneficial effect
on the tumor microenvironment. It has been also
proven that drugs of this group have antioxidant ef-
fect, which is due to their effect on ATP-dependent
K+channels and activation of antioxidant systems
of the body that can inhibit cell growth by inducing
apoptosis [14, 17]. These effects can be very useful
in the treatment of cancer, but only for those who
have no hyperinsulinemia.
Numerous scientific studies have presented a
large evidence base of hyperinsulinemia as a factor
of oncogenesis, including the organs of the repro-
ductive system, pancreas and large intestine [18,
19].
Insulin activates the processes of oncogenesis in
several ways. One of the mechanisms is associated
with the activation of the PI3K/Akt/mTOR signal-
ing pathway both through its own insulin recep-
tors (IR) and through IGF-1R, as hyperinsulinemia
reduces the level of the protein that binds IGF-1,
increasing the bioavailability of the latter.
On the other hand, early initiation of insulin
therapy or insulin therapy in doses higher than
physiological ones, stimulate lipogenesis, lead to
increased BMI, causing insulin resistance, hyperin-
sulinemia, hyperglycemia, and chronic inflamma-
tion [20].
In the treatment of patients with T2DM with
obesity or overweight, it is often impossible to
achieve physiological insulin concentrations by ex-
ogenous administration, as insulin resistance re-
quires high doses of insulin, and therefore, insulin
therapy itself promotes secondary insulin resistance,
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forming a vicious circle favorable to neoplasia [20].
It is reasonable to study the effect of insulin
analogues on carcinogenesis, as these types of in-
sulin have 6-8 times higher affinity for binding to
IGF-1R than human insulin [21]. Recent studies
and meta-analyzes have not confirmed a significant
effect of insulin analogues on oncogenesis [22, 23].
The conducted epidemiological analysis included
cases of cancer in patients with DM of the 5-year
period during 2012-2016, when the latest AHGD
with extrapancreatic mechanisms of action have not
become widely used yet. SUD and insulin drugs
are currently widely used as AHGT of the second-
and third-line therapy for patients with T2DM. This
choice is often made due to the unavailability (the
high price) of the latest drugs that reduce hyper-
glycemia without early stimulation of insulin syn-
thesis, and they also have the ability to prevent
serious complications of DM, including the abil-
ity to improve the weight of patients. These data
may be useful in the choice of AHGT for patients
with T2DM, taking into account the negative impact
of hyperinsulinemia (endogenous and exogenous),
as well as obesity on the processes of oncogenesis.
Before prescribing drugs that raise blood insulin lev-
els, it is advisable to assess the insulin-producing
reserves of the pancreas and the presence of insulin
resistance to prevent hyperinsulinemia with a view
to cancer prevention.
3. Conclusions
1. Prior to the detection of cancer in patients
with T2DM, combination therapy with met-
formin and sulfonylurea derivatives was most
often used.
2. The association between insulin therapy and
the development of cancer in patients with
T2DM was revealed.
3. For obese patients with T2DM, who receive
sulfonylurea derivatives and/or insulin, can-
cer screening is advisable.
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